Q1 Earnings Forecast for MLTX Issued By HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for MoonLake Immunotherapeutics in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.70) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.67) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.92). During the same period in the previous year, the company posted ($0.72) EPS.

A number of other analysts also recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Zacks Research raised shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Needham & Company LLC upped their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. The Goldman Sachs Group downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their target price for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Finally, Rothschild & Co Redburn upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $12.00 to $40.00 in a report on Thursday, March 19th. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $23.08.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $18.64 on Tuesday. The business’s fifty day moving average is $16.91 and its 200 day moving average is $16.89. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -5.30 and a beta of 1.20. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently made changes to their positions in the company. Cormorant Asset Management LP raised its holdings in MoonLake Immunotherapeutics by 118.4% in the 4th quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock worth $57,405,000 after acquiring an additional 2,361,260 shares during the last quarter. Janus Henderson Group PLC boosted its stake in MoonLake Immunotherapeutics by 18,782.8% during the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock valued at $27,657,000 after purchasing an additional 2,084,888 shares during the last quarter. Logos Global Management LP bought a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter worth $23,065,000. Alliancebernstein L.P. raised its stake in shares of MoonLake Immunotherapeutics by 17.8% in the second quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after purchasing an additional 171,932 shares during the last quarter. Finally, Vivo Capital LLC purchased a new position in shares of MoonLake Immunotherapeutics in the fourth quarter worth $13,180,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Key Stories Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Phase 3 trial showed strong efficacy in the lead skin disease program—majority of patients improved, prompting a sharp market reaction. MLTX stock jumps overnight
• Positive Sentiment: Retail traders piled in on buyout speculation and the favorable skin‑condition data, amplifying price moves and volume. MLTX stock garners retail attention
• Positive Sentiment: H.C. Wainwright reaffirmed a Buy rating and reiterated a $40 price target, supporting upside expectations from analysts. H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics
• Positive Sentiment: BTIG Research reconfirmed a Buy and set a $30 target, adding another institutional endorsement that may sustain upward momentum. Benzinga BTIG note
• Neutral Sentiment: H.C. Wainwright’s published 2027 quarterly EPS models show continued negative earnings (Q1–Q4 estimates range from $(0.67) to $(0.91)); the firm still rates the stock Buy but the forecasts underscore ongoing cash burn and execution risk. MarketBeat MLTX research summary

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.